{"id":"standard-dose-of-rituximab","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"20-40","effect":"Infections"},{"rate":"10-30","effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"},{"rate":"<1","effect":"Progressive multifocal leukoencephalopathy (PML)"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers multiple mechanisms of B cell destruction including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This results in rapid depletion of B cells, reducing autoimmune responses and malignant B cell populations.","oneSentence":"Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:10.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma (B-cell)"},{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Rheumatoid arthritis"},{"name":"Granulomatosis with polyangiitis (GPA)"},{"name":"Microscopic polyangiitis (MPA)"}]},"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05011422","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-11-03","conditions":"Pediatric Hematologic Malignancies","enrollment":50},{"nctId":"NCT01419561","phase":"PHASE2","title":"Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-08","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8","enrollment":140},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT05581030","phase":"PHASE1","title":"CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-05-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT07335562","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2026-04-30","conditions":"Systemic Sclerosis","enrollment":92},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT05898308","phase":"PHASE4","title":"Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-12-04","conditions":"Pemphigus, Dermatologic Disease","enrollment":133},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":60},{"nctId":"NCT04421560","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Ibrutinib and Rituximab in PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer","enrollment":37},{"nctId":"NCT02158091","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06-27","conditions":"Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT06644183","phase":"PHASE1, PHASE2","title":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"Jennifer R. Brown, MD, PhD","startDate":"2025-03-19","conditions":"Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia","enrollment":64},{"nctId":"NCT04872790","phase":"PHASE1","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-09-02","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia","enrollment":20},{"nctId":"NCT07398638","phase":"PHASE1, PHASE2","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-28","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":122},{"nctId":"NCT06350318","phase":"PHASE2","title":"Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-04-19","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma","enrollment":43},{"nctId":"NCT02315326","phase":"PHASE1, PHASE2","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-08","conditions":"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":93},{"nctId":"NCT06983821","phase":"PHASE3","title":"Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-11-10","conditions":"Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)","enrollment":36},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":"Diffuse Large B Cell Lymphoma, DLBCL, Cancer","enrollment":27},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06846463","phase":"PHASE2","title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-05-27","conditions":"Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":21},{"nctId":"NCT06342544","phase":"PHASE3","title":"Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-04-29","conditions":"Ocular Myasthenia Gravis","enrollment":128},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT04843904","phase":"PHASE1","title":"Safe Accelerated Venetoclax Escalation in CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-04-14","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT05900401","phase":"PHASE1, PHASE2","title":"Delayed Tolerance Through Mixed Chimerism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-10-01","conditions":"Kidney Failure, Kidney Transplant; Complications, Chimera","enrollment":20},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT06765317","phase":"PHASE2","title":"A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-01-16","conditions":"Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma","enrollment":42},{"nctId":"NCT06047171","phase":"PHASE2","title":"Rescue of Nephrons With ALE.F02 (RENAL-F02)","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2023-09-07","conditions":"Glomerulonephritis Rapidly Progressive","enrollment":80},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT03164473","phase":"PHASE3","title":"Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-03-07","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":98},{"nctId":"NCT07225439","phase":"PHASE1","title":"Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","status":"NOT_YET_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2025-12","conditions":"Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":15},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT04833114","phase":"PHASE3","title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GWT-TUD GmbH","startDate":"2021-04-30","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":306},{"nctId":"NCT04074187","phase":"PHASE2, PHASE3","title":"A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":21},{"nctId":"NCT06341205","phase":"PHASE3","title":"Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-02-04","conditions":"Membranous Nephropathy","enrollment":120},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07124936","phase":"PHASE1, PHASE2","title":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-07-30","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":97},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT03013218","phase":"PHASE1","title":"A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)","status":"COMPLETED","sponsor":"ALX Oncology Inc.","startDate":"2017-02-03","conditions":"Metastatic Cancer, Solid Tumor, Advanced Cancer","enrollment":174},{"nctId":"NCT04935177","phase":"PHASE3","title":"Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2021-10-14","conditions":"Kidney Transplantation in Highly Sensitized Patients","enrollment":64},{"nctId":"NCT05276310","phase":"PHASE1","title":"A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy","status":"RECRUITING","sponsor":"ImmuneOncia Therapeutics Inc.","startDate":"2022-06-02","conditions":"Advanced Cancer","enrollment":62},{"nctId":"NCT07035561","phase":"PHASE2","title":"Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis","status":"COMPLETED","sponsor":"Shereen Medhat Mohammed Elsayed Nassar","startDate":"2023-06-01","conditions":"Hypersenstivity Pneumonitis, ILD","enrollment":30},{"nctId":"NCT07002099","phase":"PHASE2","title":"Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Lymphomas","enrollment":26},{"nctId":"NCT05050214","phase":"PHASE2","title":"Obinutuzumab in Primary MN","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2022-02-18","conditions":"Membranous Nephropathy","enrollment":20},{"nctId":"NCT06730542","phase":"PHASE1","title":"Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2025-04-17","conditions":"CNS Lymphoma","enrollment":20},{"nctId":"NCT03623373","phase":"PHASE2","title":"Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-11-29","conditions":"Mantle Cell Lymphoma","enrollment":13},{"nctId":"NCT03571568","phase":"PHASE1, PHASE2","title":"A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL","status":"RECRUITING","sponsor":"BioInvent International AB","startDate":"2018-05-16","conditions":"Indolent B-Cell Non-Hodgkin Lymphoma","enrollment":140},{"nctId":"NCT03719131","phase":"PHASE2","title":"Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-06-05","conditions":"Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma","enrollment":15},{"nctId":"NCT01661881","phase":"PHASE2","title":"Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-08-16","conditions":"Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT03994783","phase":"PHASE3","title":"Transplant Antibody-Mediated Rejection: Guiding Effective Treatments","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2019-07-17","conditions":"Kidney Transplant Rejection, Antibody-mediated Rejection","enrollment":3},{"nctId":"NCT05862766","phase":"EARLY_PHASE1","title":"Isatuximab in Lung Transplant Recipients","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2024-12-01","conditions":"Antibody-mediated Rejection, Allosensitization","enrollment":""},{"nctId":"NCT05545384","phase":"PHASE3","title":"Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04","conditions":"Acute Demyelinating Syndrome","enrollment":86},{"nctId":"NCT05303792","phase":"PHASE2","title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-09","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":68},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT02378298","phase":"PHASE4","title":"Rituximab (RTX) Therapy in Patients With Active TAO","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"Ophthalmopathy, Thyroid-Associated","enrollment":38},{"nctId":"NCT03206671","phase":"PHASE3","title":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Muenster","startDate":"2017-08-03","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":650},{"nctId":"NCT04419389","phase":"PHASE1, PHASE2","title":"APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)","status":"TERMINATED","sponsor":"Aprea Therapeutics","startDate":"2021-03-02","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT02222155","phase":"PHASE2","title":"Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-04","conditions":"ANCA-associated Vasculitis","enrollment":42},{"nctId":"NCT06871007","phase":"PHASE1, PHASE2","title":"Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2024-09-01","conditions":"Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, Nivolumab","enrollment":22},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT04517435","phase":"PHASE1, PHASE2","title":"ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"Deepa Jagadeesh","startDate":"2021-04-28","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":13},{"nctId":"NCT04871191","phase":"PHASE3","title":"Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03","conditions":"Granulomatosis with Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":42},{"nctId":"NCT03495960","phase":"PHASE2","title":"Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-06-15","conditions":"Primary Central Nervous System Lymphoma","enrollment":72},{"nctId":"NCT06792253","phase":"PHASE3","title":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2025-01-06","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":416},{"nctId":"NCT03467373","phase":"PHASE1","title":"A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-03-13","conditions":"B-Cell Lymphoma, Non-Hodgkin Lymphoma","enrollment":111},{"nctId":"NCT02950051","phase":"PHASE3","title":"Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2016-12-13","conditions":"Chronic Lymphocytic Leukemia","enrollment":926},{"nctId":"NCT06750991","phase":"PHASE2","title":"CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"DLBCL","enrollment":34},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT06646497","phase":"PHASE2","title":"Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-01","conditions":"Aplastic Anemia","enrollment":52},{"nctId":"NCT06573645","phase":"PHASE3","title":"A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Xia Yi","startDate":"2024-08-23","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":428},{"nctId":"NCT05864742","phase":"PHASE2","title":"Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2023-09-07","conditions":"Mantle Cell Lymphoma Refractory","enrollment":40},{"nctId":"NCT04555811","phase":"PHASE1","title":"FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2020-09-22","conditions":"NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":7},{"nctId":"NCT04933617","phase":"PHASE1","title":"Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-24","conditions":"Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma","enrollment":8},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT06086197","phase":"PHASE2","title":"A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-10-01","conditions":"Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory","enrollment":41},{"nctId":"NCT02073097","phase":"PHASE1, PHASE2","title":"Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-01-28","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT05966233","phase":"PHASE2","title":"R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-01","conditions":"Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":""},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT02451111","phase":"PHASE2","title":"Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2015-11-06","conditions":"Follicular Lymphoma","enrollment":190},{"nctId":"NCT04656431","phase":"PHASE1","title":"Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma","status":"UNKNOWN","sponsor":"James Rubenstein","startDate":"2021-06-29","conditions":"Primary CNS Lymphoma","enrollment":25},{"nctId":"NCT04220008","phase":"PHASE2","title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-29","conditions":"Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Standard dose of rituximab","genericName":"Standard dose of rituximab","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}